News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Month Year

Sep 20, 2019

Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
Sep 18, 2019

Astellas Celebrates Decade of Service by Volunteering 80,000 Hours to Help Local Communities

- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 -
- Photos 3
Sep 16, 2019

Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -
Sep 11, 2019

Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas
Aug 27, 2019

Astellas Announces Key Leadership Appointments within Oncology and Patient Centricity Organizations
- Photos 2
Aug 21, 2019

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy
Aug 6, 2019

Astellas Announces Appointment of David Fryrear as New Global Head of Clinical and Research Quality Assurance Organization
- Photos 1
Aug 5, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms
Jul 16, 2019

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-
Jul 10, 2019

Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales

Glinski to Oversee US Sales for XTANDI
- Photos 1
Jun 3, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-
May 30, 2019

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -
May 20, 2019

Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -
May 9, 2019

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary
- Photos 1
May 5, 2019

New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin

- Data Presented at the American Urological Association 2019 Annual Meeting -
Apr 25, 2019

Astellas Statement on U.S. Department of Justice Settlement Related to Patient Co-Pay Assistance Foundations
Apr 3, 2019

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
- Photos 3
Apr 1, 2019

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy

- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -
Mar 28, 2019

Astellas: Five Consecutive Years of Perfect Equality Scores
Mar 28, 2019

Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

- Companies Plan to Submit Biologics License Application Later This Year -
Mar 26, 2019

Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)

- Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -
Mar 18, 2019

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
- Photos 1
Feb 28, 2019

Astellas Announces Key Leadership Promotions and New Hire in Legal, IP and Immuno-Oncology
Feb 20, 2019

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making
Feb 11, 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Data to be presented at the 2019 Genitourinary Cancers Symposium
Jan 10, 2019

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
- Photos 4
Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Dec 14, 2018

Astellas Acquires Potenza Therapeutics

Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline
- Photos 1
Dec 12, 2018

Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing
- Photos 1
Dec 10, 2018

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Dec 3, 2018

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Nov 28, 2018

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs -
Nov 20, 2018

Astellas Global Health Foundation Launches - Foundation to Support Improving Access to Health for Underserved Populations -
Nov 20, 2018

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration

Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+
Nov 19, 2018

Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -
Nov 12, 2018

Astellas Appoints Eloiza Domingo-Snyder to Head of Diversity and Inclusion
- Photos 1
Oct 9, 2018

Astellas Details Progress and Commitment to Patients and the Community in the Company's Americas 2017 Corporate Social Responsibility Report Card
- Photos 1
Oct 4, 2018

Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer Congress

Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
- Photos 1
Sep 25, 2018

Working Mother Magazine names Astellas among 100 best companies in the US across all industries

Astellas ranked in recognition of its commitment and support for working mothers
Sep 24, 2018

Astellas Farma Brasil named one of the best companies to work for in Brazil

Astellas recognized by Great Place to Work® Institute
Sep 24, 2018

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)
Sep 21, 2018

Astellas Oncology Announces C3 Prize® Celebrity Partnership and Category Winners

Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
Sep 18, 2018

Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US
- Photos 1
Sep 14, 2018

Astellas Named a PM360 Trailblazer 2018 "Company of the Year"

--Additional marketing award received for Best Video/TV Campaign--
- Photos 1
Sep 13, 2018

More than 800 Astellas Employees Volunteer for 16 Community Organizations as Part of Ninth Annual Changing Tomorrow Day
- Photos 3
Sep 12, 2018

Astellas Announces Launch of "What's Next Sweepstakes" with Laila Ali

Winner Will Attend Live Taping of ABC's "Dancing with the Stars"
Aug 23, 2018

Astellas Appoints Shontelle Dodson to Senior Vice President Health Systems
- Photos 1
Aug 23, 2018

Astellas Promotes Rodrigo Fernandez to Vice President, Latin America
- Photos 1
Aug 22, 2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials
Aug 16, 2018

Astellas Promotes David Abbott to National Vice President Key Account Management
- Photos 1

Show per page

Follow Us On Social Media

Stay Connected

Get only the email alerts you want.

Media Contacts

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

Download Fact Sheet

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products

Explore U.S. Products